TAMPA, Fla., Sept. 15, 2015 /PRNewswire/ -- Oxis Biotech, Inc. (OXIS), a wholly owned subsidiary of Oxis International, Inc. [OTC: OXIS] and [Euronext Paris: OXI.PA], announced today that James L. Nelson has joined its Business Advisory Board. Oxis is in the process of building a world class Advisory Board to assist management in strategy, development and execution. The Business Advisory Board members will become members of the Oxis Board of Directors upon a successful up-listing to the NASDAQ exchange.
James L. Nelson has served as a director and member of the audit committee of Icahn Enterprises L.P. (IEP) and its general partner, Icahn Enterprises G.P., Inc., since June 2001. Since June 2011, Mr. Nelson has served as a director and member of the compensation, governance and strategic alternatives committees of Voltari Corporation and, since January 2012, Chairman of its Board of Directors. Since April 2014, Mr. Nelson has served as a director and member of the audit committee, of Herbalife Ltd. (HLF), a nutrition company.
Mr. Nelson has previously served as a director and member of the audit committee of Tropicana Entertainment, The Viskase Companies, Inc., American Entertainment Properties, Atlantic Coast Entertainment Holdings, Inc., Cequel Communications, an owner and operator of a large cable television system, Take Two Interactive Software, Inc., a publisher, developer, and distributor of video games.
Mr. Nelson was Chairman and Chief Executive Officer of Eaglescliff Corporation, a specialty investment banking, consulting and wealth management company from 1986 through 2009. From 1995 through 1999, Mr. Nelson was Chief Executive Officer and Co-Chairman of Orbitex Management, Inc., a financial services company in the mutual fund sector.
"We are honored to have Jim as a member of our Business Advisory Board. Jim brings a wealth of experience and will help guide us while we complete the final requirements in our plans for up-listing to NASDAQ's main exchange," said Anthony Cataldo.
"I'm extremely pleased to be joining the Advisory Board of Oxis, and I look forward to being part of this exciting and socially rewarding industry," said Mr. Nelson.
About Oxis Biotech - Oxis Biotech develops innovative drugs focused on the treatment of cancer and other unmet medical needs. OXIS' lead drug candidate, DT2219ARL is a novel bispecific scFv recombinant fusion protein-drug conjugate composed of the variable regions of the heavy and light chains of anti-CD19 and anti-CD22 antibodies and a modified form of diphtheria toxin as its cytotoxic drug payload. DT2219ARL simultaneously targets cancer cells expressing the CD19 receptor or CD22 receptor or both receptors. When DT2219ARL binds to cancer cells, the cancer cells internalize DT2219ARL and are killed due to the action of drug's cytotoxic payload. DT2219ARL has demonstrated success in early human clinical trials in patients with relapsed/refractory B-cell lymphoma or leukemia. OXS-4235 is a small molecule therapeutic candidate targeting the treatment of multiple myeloma and associated osteolytic lesions. In in vitro and in vivo models of multiple myeloma and osteoporosis, OXS-4235 demonstrated the ability to kill multiple myeloma cells, and decrease osteolytic lesions in bone. OXIS' lead drug candidate, OXS-2175, is a small molecule therapeutic candidate targeting the treatment of triple-negative breast cancer (TNBC). In in vitro and in vivo models of TNBC, OXS-2175 demonstrated the ability to inhibit metastasis. For more information about Oxis Biotech, please visit http://www.oxis.com.
James L. Nelson has served as a director and member of the audit committee of Icahn Enterprises L.P. (IEP) and its general partner, Icahn Enterprises G.P., Inc., since June 2001. Since June 2011, Mr. Nelson has served as a director and member of the compensation, governance and strategic alternatives committees of Voltari Corporation and, since January 2012, Chairman of its Board of Directors. Since April 2014, Mr. Nelson has served as a director and member of the audit committee, of Herbalife Ltd. (HLF), a nutrition company.
Mr. Nelson has previously served as a director and member of the audit committee of Tropicana Entertainment, The Viskase Companies, Inc., American Entertainment Properties, Atlantic Coast Entertainment Holdings, Inc., Cequel Communications, an owner and operator of a large cable television system, Take Two Interactive Software, Inc., a publisher, developer, and distributor of video games.
Mr. Nelson was Chairman and Chief Executive Officer of Eaglescliff Corporation, a specialty investment banking, consulting and wealth management company from 1986 through 2009. From 1995 through 1999, Mr. Nelson was Chief Executive Officer and Co-Chairman of Orbitex Management, Inc., a financial services company in the mutual fund sector.
"We are honored to have Jim as a member of our Business Advisory Board. Jim brings a wealth of experience and will help guide us while we complete the final requirements in our plans for up-listing to NASDAQ's main exchange," said Anthony Cataldo.
"I'm extremely pleased to be joining the Advisory Board of Oxis, and I look forward to being part of this exciting and socially rewarding industry," said Mr. Nelson.
About Oxis Biotech - Oxis Biotech develops innovative drugs focused on the treatment of cancer and other unmet medical needs. OXIS' lead drug candidate, DT2219ARL is a novel bispecific scFv recombinant fusion protein-drug conjugate composed of the variable regions of the heavy and light chains of anti-CD19 and anti-CD22 antibodies and a modified form of diphtheria toxin as its cytotoxic drug payload. DT2219ARL simultaneously targets cancer cells expressing the CD19 receptor or CD22 receptor or both receptors. When DT2219ARL binds to cancer cells, the cancer cells internalize DT2219ARL and are killed due to the action of drug's cytotoxic payload. DT2219ARL has demonstrated success in early human clinical trials in patients with relapsed/refractory B-cell lymphoma or leukemia. OXS-4235 is a small molecule therapeutic candidate targeting the treatment of multiple myeloma and associated osteolytic lesions. In in vitro and in vivo models of multiple myeloma and osteoporosis, OXS-4235 demonstrated the ability to kill multiple myeloma cells, and decrease osteolytic lesions in bone. OXIS' lead drug candidate, OXS-2175, is a small molecule therapeutic candidate targeting the treatment of triple-negative breast cancer (TNBC). In in vitro and in vivo models of TNBC, OXS-2175 demonstrated the ability to inhibit metastasis. For more information about Oxis Biotech, please visit http://www.oxis.com.
1
